Travere Therapeutics Inc (Travere) is a biopharmaceutical company focused on discovering, developing, and commercializing treatments for rare kidney and metabolic diseases, particularly where significant unmet medical needs exist. The company is advancing a pipeline that includes several late-stage clinical programs.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Travere is actively engaged in research and development efforts to address unmet needs in rare kidney and metabolic diseases. The company's pipeline includes products targeting IgA Nephropathy (IgAN), Focal Segmental Glomerulosclerosis (FSGS), Classical Homocystinuria (HCU), and Cystinuria. Key initiatives include the development of FILSPARI (sparsentan) for IgAN and FSGS, and pegtibatinase (TVT-058) for HCU. The company is committed to expanding its pipeline through licenses and acquisitions of products that serve rare disease patients with serious unmet medical needs. Its R&D activities are managed through various programs focusing on the development of sparsentan, pegtibatinase, and other pipeline products. The R&D unit is responsible for conducting clinical and nonclinical development activities, including clinical trials, drug material development, and manufacturing drug product supplies to support clinical development. The unit also manages indirect costs that benefit multiple development programs and enhances pharmaceutical development capabilities. The company offers several pipeline products, including FILSPARI (sparsentan) for IgAN and FSGS, and pegtibatinase (TVT-058) for HCU. In FY2025, the company spent US$206 million on R&D, which as a percentage of revenue, stood at 41.9% and declined 5.2% YoY. As of December 2025, the company has a patent portfolio for Filspari (sparsentan) comprised of six distinct patent families, one of which is exclusively licensed from Ligand, and five owned by the company. The patent portfolio for pegtibatinase includes six distinct patent families obtained from the acquisition of Orphan Technologies Limited. The patent portfolio for Thiola is comprised of a patent family exclusively licensed from Mission Pharmacal.